Please login to the form below

Not currently logged in
Email:
Password:

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.

Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.

Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.

Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.

“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”

Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.

Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.

4th February 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics